2025-01-07 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance Comparison & Divergence:**

Merck & Co Inc (MRK) is a leading pharmaceutical company developing and manufacturing medicines and vaccines.  The cumulative return of MRK is 64.63%, significantly lagging behind the S&P 500 (VOO) with a cumulative return of 117.62%. The difference is -53.0%, placing it at the 9.6th percentile of its historical range of divergence from the S&P 500.  This indicates underperformance relative to the broader market over the analyzed period.  The provided alpha consistently shows negative values, indicating underperformance relative to the market benchmark, while the high beta signifies greater volatility than the market.

**2. Recent Price Movement:**

* **Closing Price:** $99.72
* **5-Day Moving Average:** $99.18
* **20-Day Moving Average:** $99.82
* **60-Day Moving Average:** $101.41

The price is slightly below the 20-day moving average, suggesting a minor short-term bearish trend,  while being further below the 60-day moving average, indicating a more pronounced longer-term bearish trend.

**3. Technical Indicators & Expected Return:**

* **RSI:** 43.23 (Below 50, suggesting bearish momentum)
* **PPO:** 0.07 (Positive, but weak, suggesting slightly bullish momentum)
* **Relative Strength Change (20-day):** +0.3 (Minor short-term upward trend)
* **Expected Return (vs. S&P 500):** 56.4% (over 2 years)  This high expected return needs to be considered within the context of the current underperformance and the uncertainties inherent in long-term projections.


**4. Recent Earnings Analysis:**

The provided earnings data reveals inconsistencies.  There are duplicate entries for 2024-11-06.  Analyzing the unique data points:

* **Revenue:** Revenue shows a generally increasing trend, although there was a slight dip in Q4 2023.
* **EPS:** EPS fluctuates, with a peak in August 2024 followed by a decline in November 2024.  The consistency of data is questionable given the duplicates. A more complete dataset is required for a thorough analysis.

**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue growth is positive overall but shows some quarter-to-quarter fluctuation.  Profit margins are relatively high and stable, though a slight decrease is noticeable in Q4 2023 and Q3 2024 compared to earlier quarters.

* **Capital and Profitability:**  Equity has generally increased, though it declined from Q1 to Q4 2023. ROE fluctuates significantly, experiencing a substantial negative value in Q4 2023 before rebounding to positive levels.

Further investigation is necessary to understand the reasons behind the fluctuations in ROE and the inconsistencies in the data.


**6. News and Recent Issues:**

No recent news or analyst opinions are provided.  Information regarding recent market outlook is absent. This information is crucial for a comprehensive assessment.

**7. Overall Analysis:**

MRK has significantly underperformed the S&P 500 over the analyzed period, indicated by both cumulative return and consistently negative alpha values.  While the expected return is positive, the high beta suggests higher volatility.  Technical indicators present a mixed picture.  Recent earnings show inconsistencies in the data provided, needing clarification and complete data.  Missing market outlook and analyst opinions limit the comprehensive analysis.  Overall, a more thorough review with complete and accurate data is needed to form a well-informed investment decision.

**8. Recommendations:**

Further analysis is recommended incorporating the missing data and news events. A deeper dive into the reasons behind the fluctuations in EPS, ROE and profit margins is required.  Considering the inconsistent data and the significant underperformance relative to the market, a cautious approach is advised until a more comprehensive analysis can be performed.
